Clinical trial
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal…
NCT00087763 · Eyetech Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00087763 |
|---|---|
| Title | Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) |
| Official title | A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) |
| Lead sponsor | Eyetech Pharmaceuticals, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | Macugen ™ (pegaptanib sodium injection) |
| Enrollment | 135 |
| Start date | Mar 1, 2004 |
| Completion | May 1, 2006 |
| First posted | Jul 16, 2004 |
| Last update posted | May 3, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: